These results additionally suggested a mechanism whereby patient tumors with high YY1 expression and, therefore, low DR5 expression (repressed by YY1), would experience higher apoptosis resistance to both immune and chemotherapeutic drugs and, consequently, develop tumors of higher grades as a consequence of tumor unresponsiveness to therapy. Here, TNFRSF10B is linked to neoplasm.